$HRGN Balance Sheet | Understand Stock

$HRGN

$2.35 +$0.05 (2.17%) Close

$HRGN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets (Current Period Unaudited)

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Oct 31, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Current assets:
Cash
Restricted cash
Grant receivable
Cash and cash equivalents
Short-term investments
Accounts receivable
Inventory
Prepaid research and development
Prepaid expenses and other current assets
Total current assets
Property, plant and equipment, net
Right-of-use assets, net
Other long-term assets
Deferred financing costs
Long-term prepaid contracts
Total assets

Current liabilities:
Accounts payable
Accrual for contingency matter
Warrant liability
Accrued and other current liabilities
Deferred revenue
Insurance premium financing payable
Insurance Premium Financing Payable
Total insurance premium financing payable
Convertible debt – related party
Related Party
Total convertible debt – related party
Operating lease liability
Total current liabilities

Notes payable, net of current portion
Operating lease liability, net of current portion
Total liabilities
Series E convertible preferred stock, par value $0.01 per share, 5,000 shares authorized; 0 and 4,180 shares issued and outstanding at December 31, 2023 and 2022, respectively
Stockholders’ (deficit) equity:
Preferred stock, $0.01 par value; 2,000,000 shares authorized, none issued and outstanding
Common stock, par value $0.01 per share, 60,000,000 shares authorized; 17,580,744 shares issued and outstanding at each of June 30, 2026 and December 31, 2025
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total stockholders’ (deficit) equity
Total liabilities and stockholders’ (deficit) equity

Comments